Azenta Reports Mixed Q3 Fiscal 2026 Results Amid Turnaround Efforts — Azenta, Inc.

Event summary

Azenta reported $161 million in revenue for Q3 Fiscal 2026, up 12% YoY, with organic growth at 9%.
Sample Management Solutions revenue grew 14% YoY to $88 million, while Multiomics revenue increased 10% YoY to $73 million.
Adjusted EBITDA was $18.5 million, with a margin of 11.4%, down 60 basis points YoY.
The company completed the sale of B Medical Systems on July 1, 2026.
Azenta repurchased $50 million worth of shares under its share repurchase program.

The big picture

Azenta's Q3 Fiscal 2026 results reflect ongoing challenges in the life sciences sector, with mixed performance across its segments. The company is navigating a turnaround phase, focusing on cost management and strategic initiatives to drive growth. The divestiture of B Medical Systems marks a significant step in streamlining operations, while share repurchases indicate confidence in the company's long-term prospects.

What we're watching

Revenue Stability: Whether Azenta can sustain its revenue growth amid a challenging market backdrop.
Cost Management: The pace at which the company can improve its gross margin, currently impacted by fixed-cost absorption and quality remediation costs.
Turnaround Execution: How effectively Azenta can execute its strategic priorities to drive long-term operational efficiencies and productivity improvements.